164 related articles for article (PubMed ID: 10542221)
1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.
Delgado M; Ganea D
J Biol Chem; 1999 Nov; 274(45):31930-40. PubMed ID: 10542221
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
Delgado M; Munoz-Elias EJ; Kan Y; Gozes I; Fridkin M; Brenneman DE; Gomariz RP; Ganea D
J Biol Chem; 1998 Nov; 273(47):31427-36. PubMed ID: 9813054
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
Delgado M; Ganea D
J Biol Chem; 2001 Jan; 276(1):369-80. PubMed ID: 11029467
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
5. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
Delgado M; Ganea D
J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
Delgado M; Ganea D
J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
Delgado M; Ganea D
J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
[TBL] [Abstract][Full Text] [Related]
10. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Neuroimmunol; 1999 May; 96(2):167-81. PubMed ID: 10337915
[TBL] [Abstract][Full Text] [Related]
11. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP
J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
Delgado M; Leceta J; Ganea D
J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies.
Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP
J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
Sun W; Tadmori I; Yang L; Delgado M; Ganea D
J Neuroimmunol; 2000 Jul; 107(1):88-99. PubMed ID: 10808055
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
Delgado M; Ganea D
J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 Oct; 297(5):1181-5. PubMed ID: 12372411
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages.
MartÃnez C; Delgado M; Pozo D; Leceta J; Calvo JR; Ganea D; Gomariz RP
J Leukoc Biol; 1998 May; 63(5):591-601. PubMed ID: 9581803
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
Martinez C; Delgado M; Gomariz RP; Ganea D
J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]